Vyondys 53

Showing 1 posts of 1 posts found.

FDA U-turns to approve Sarepta’s Vyondys 53 in Duchenne muscular dystrophy

December 13, 2019
Medical Communications, Sales and Marketing FDA, Vyondys 53, pharma, sarepta

The FDA has surprised industry pundits by choosing to approve Sarepta’s Vyondys 53 under an accelerated pathway for the treatment …

The Gateway to Local Adoption Series

Latest content